Paulo José Lorenzoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paulo José Lorenzoni has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Rosana Herminia Scola
Universidade Federal do Paraná, Curitiba PR, Brazil
35 shared publications - Cláudia Suemi Kamoi Kay
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
30 shared publications - Renata Dal-Prá Ducci
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
29 shared publications - Otto Jesus Hernandez Fustes
Universidade Federal do Paraná, Brazil
26 shared publications - Lineu Cesar Werneck
Universidade Federal do Paraná
25 shared publications - Paula Raquel Do Vale Pascoal Rodrigues
Service of Neuromuscular Disorders, Division of Neurology, Department of Internal Medicine, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
9 shared publications
Latest Publications
- 20 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (8) , 475
Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene
Background Neuromuscular disorders (NMDs) affect approximately 1 in 1,000 individuals and are clinically and genetically heterogeneous. Despite advances in genomic diagnostics, many cases remain unsolved after initial sequencing. Bioinformatic reanalysis approaches provide opportunities to identify missed variants and establish novel disease genes. Methods Preexisting next-generation sequencing datasets from 101 undiagnosed NMD families were reanalyzed using the RD-Connect Genome-Phenome Analysis Platform. The data comprised clinical exome sequencing (45 families), whole exome sequencing (31 families), and whole genome sequencing (25 families). Variant prioritization incorporated population frequency, Human Phenotype Ontology terms, in silico predictions, and genotype–phenotype correlation. Results Reanalysis identified causative variants in 17 out of 101 previously unsolved families (16.83% diagnostic yield). Eight cases harbored coding variants in known NMD genes (RYR1, AGRN, SCN4A, TTN, MYH2, GOLGA2) consistent with the observed phenotype. In five cases, intronic variants in known NMD genes (COL6A3, SGCA, DOK7, DYSF, CHRND) were considered causative following in silico predictions and careful correlation with the phenotype. One case had an extended phenotype (PTPN11), and one case had a dual diagnosis (MYH2, KIF21A). A novel ATP2A2 missense variant was identified in two unrelated families, establishing ATP2A2 as a new NMD gene. Conclusion Research-based reanalysis of preexisting NGS data improved diagnostic yield of previously unsolved cases consistent with previous literature, reinforcing the utility of in-depth, phenotype-driven reanalysis with expert review. Our study provided 17 families with unsolved NMDs with a diagnosis after having waited for a decade. This supports the routine reanalysis of unsolved NGS data, highlighting its potential to reclassify variants of unknown significance and reveal novel genes and pathomechanisms in NMDs.
- 20 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (8) , 475
Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene
Background Neuromuscular disorders (NMDs) affect approximately 1 in 1,000 individuals and are clinically and genetically heterogeneous. Despite advances in genomic diagnostics, many cases remain unsolved after initial sequencing. Bioinformatic reanalysis approaches provide opportunities to identify missed variants and establish novel disease genes. Methods Preexisting next-generation sequencing datasets from 101 undiagnosed NMD families were reanalyzed using the RD-Connect Genome-Phenome Analysis Platform. The data comprised clinical exome sequencing (45 families), whole exome sequencing (31 families), and whole genome sequencing (25 families). Variant prioritization incorporated population frequency, Human Phenotype Ontology terms, in silico predictions, and genotype–phenotype correlation. Results Reanalysis identified causative variants in 17 out of 101 previously unsolved families (16.83% diagnostic yield). Eight cases harbored coding variants in known NMD genes (RYR1, AGRN, SCN4A, TTN, MYH2, GOLGA2) consistent with the observed phenotype. In five cases, intronic variants in known NMD genes (COL6A3, SGCA, DOK7, DYSF, CHRND) were considered causative following in silico predictions and careful correlation with the phenotype. One case had an extended phenotype (PTPN11), and one case had a dual diagnosis (MYH2, KIF21A). A novel ATP2A2 missense variant was identified in two unrelated families, establishing ATP2A2 as a new NMD gene. Conclusion Research-based reanalysis of preexisting NGS data improved diagnostic yield of previously unsolved cases consistent with previous literature, reinforcing the utility of in-depth, phenotype-driven reanalysis with expert review. Our study provided 17 families with unsolved NMDs with a diagnosis after having waited for a decade. This supports the routine reanalysis of unsolved NGS data, highlighting its potential to reclassify variants of unknown significance and reveal novel genes and pathomechanisms in NMDs.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-007
The skin-wrinkling test: principles and clinical applications
Cutaneous wrinkling is a normal phenomenon that occurs on the palms in a reversible manner and results from vasoconstriction influenced by vasomotor function. It can be assessed through the skin-wrinkling test following water immersion, with the absence or reduction of wrinkling being associated with disorders affecting the dense network of sympathetic nerves in these regions. The literature suggests that this test may serve as a screening tool for small-fiber neuropathy, particularly in settings in which biopsy is not available. It is a rapid, inexpensive, and easily-accessible test. We herein review the principles of the skin-wrinkling test, its pathophysiology, and its clinical indications as a tool to evaluate the sympathetic component of the autonomic nervous system.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-007
Open AccessThe skin-wrinkling test: principles and clinical applications
Cutaneous wrinkling is a normal phenomenon that occurs on the palms in a reversible manner and results from vasoconstriction influenced by vasomotor function. It can be assessed through the skin-wrinkling test following water immersion, with the absence or reduction of wrinkling being associated with disorders affecting the dense network of sympathetic nerves in these regions. The literature suggests that this test may serve as a screening tool for small-fiber neuropathy, particularly in settings in which biopsy is not available. It is a rapid, inexpensive, and easily-accessible test. We herein review the principles of the skin-wrinkling test, its pathophysiology, and its clinical indications as a tool to evaluate the sympathetic component of the autonomic nervous system.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-006
Clinical profile and quality of life in late-onset and very-late-onset myasthenia gravis: a cross-sectional study
The incidence of late-onset and very-late-onset myasthenia gravis (MG) has increased worldwide, but national data in Brazil remain scarce. Characterizing the clinical profile and quality of life (QoL) of these patients is essential to improve care strategies. To describe the clinical profile and assess QoL of patients with late- and very-late-onset MG followed at a Brazilian tertiary hospital, comparing them with early-onset MG patients. Cross-sectional observational study including adult MG patients followed at a tertiary university hospital. Demographic, clinical, serological, neurophysiological, and radiological data were collected. Disease severity was assessed using the Myasthenia Gravis Composite (MGC) and Quantitative Myasthenia Gravis (QMG) scales. Furthermore, QoL was assessed using the 15-item Myasthenia Gravis QoL questionnaire (MG-QOL15). Correlation analyses were performed between MG-QOL15, MGC, and QMG scores. In total, 28 MG patients were included: 13 early-onset, 7 late-onset, and 8 very-late-onset. Male predominance, shorter disease duration, and absence of thymectomy were more frequent in the late and very-late-onset groups. These subgroups also showed better symptom control and perceived QoL, particularly the very-late-onset group. The MG-QOL15 scores showed a moderate correlation with MGC and a weaker correlation with QMG. Late-onset and very-late-onset MG patients showed satisfactory QoL and clinical profiles, consistent with international data. These correlations reinforce the complementary role of patient-reported outcomes alongside objective clinical scales. Further studies with larger cohorts and longitudinal follow-up are needed.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (07) , 001-006
Open AccessClinical profile and quality of life in late-onset and very-late-onset myasthenia gravis: a cross-sectional study
The incidence of late-onset and very-late-onset myasthenia gravis (MG) has increased worldwide, but national data in Brazil remain scarce. Characterizing the clinical profile and quality of life (QoL) of these patients is essential to improve care strategies. To describe the clinical profile and assess QoL of patients with late- and very-late-onset MG followed at a Brazilian tertiary hospital, comparing them with early-onset MG patients. Cross-sectional observational study including adult MG patients followed at a tertiary university hospital. Demographic, clinical, serological, neurophysiological, and radiological data were collected. Disease severity was assessed using the Myasthenia Gravis Composite (MGC) and Quantitative Myasthenia Gravis (QMG) scales. Furthermore, QoL was assessed using the 15-item Myasthenia Gravis QoL questionnaire (MG-QOL15). Correlation analyses were performed between MG-QOL15, MGC, and QMG scores. In total, 28 MG patients were included: 13 early-onset, 7 late-onset, and 8 very-late-onset. Male predominance, shorter disease duration, and absence of thymectomy were more frequent in the late and very-late-onset groups. These subgroups also showed better symptom control and perceived QoL, particularly the very-late-onset group. The MG-QOL15 scores showed a moderate correlation with MGC and a weaker correlation with QMG. Late-onset and very-late-onset MG patients showed satisfactory QoL and clinical profiles, consistent with international data. These correlations reinforce the complementary role of patient-reported outcomes alongside objective clinical scales. Further studies with larger cohorts and longitudinal follow-up are needed.
- Open Access
- 17 April 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 57
Somatosensory Evoked Potentials in Spinocerebellar Ataxia Type 3 and Type 10
Spinocerebellar ataxias (SCAs) are heterogeneous neurodegenerative disorders with variable phenotypes. Somatosensory evoked potentials (SSEPs) provide insights into the integrity of the dorsal-lemniscal pathway. This study aimed to evaluate SSEP findings in patients with SCA3 and SCA10 and compare their neurophysiological profiles. We conducted a cross-sectional study including 20 SCA3 patients and 20 SCA10 patients under follow-up at a tertiary ataxia clinic in Southern Brazil. Clinical assessment comprised demographic, genetic, and phenotypic characterization, including the Scale for the Assessment and Rating of Ataxia (SARA). SSEPs were recorded bilaterally after median and tibial nerve stimulation, assessing latencies and amplitudes of N9, N20, N21, and P40 potentials, as well as interpotential intervals. Examinations were classified as normal or abnormal, and abnormalities were categorized. Abnormal SSEPs were detected in 18 SCA3 patients (90%) and in 3 SCA10 patients (15%) ( p < 0.001). In SCA3, abnormalities predominantly involved central generators. In contrast, most SCA10 patients exhibited normal SSEPs, with only a few isolated cortical responses and interval abnormalities. No significant associations were found between SSEP abnormalities and demographic, clinical, imaging, or genetic variables in either group. SCA3 shows widespread somatosensory dysfunction, whereas SCA10 patients, particularly in Southern Brazil, show preserved SSEPs consistent with pure cerebellar ataxia. These findings highlight distinct neurophysiological signatures in SCAs, reinforcing their heterogeneity and supporting SSEPs as candidate markers for differential characterization, requiring validation.
- 17 April 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (3) , 57
Open AccessSomatosensory Evoked Potentials in Spinocerebellar Ataxia Type 3 and Type 10
Spinocerebellar ataxias (SCAs) are heterogeneous neurodegenerative disorders with variable phenotypes. Somatosensory evoked potentials (SSEPs) provide insights into the integrity of the dorsal-lemniscal pathway. This study aimed to evaluate SSEP findings in patients with SCA3 and SCA10 and compare their neurophysiological profiles. We conducted a cross-sectional study including 20 SCA3 patients and 20 SCA10 patients under follow-up at a tertiary ataxia clinic in Southern Brazil. Clinical assessment comprised demographic, genetic, and phenotypic characterization, including the Scale for the Assessment and Rating of Ataxia (SARA). SSEPs were recorded bilaterally after median and tibial nerve stimulation, assessing latencies and amplitudes of N9, N20, N21, and P40 potentials, as well as interpotential intervals. Examinations were classified as normal or abnormal, and abnormalities were categorized. Abnormal SSEPs were detected in 18 SCA3 patients (90%) and in 3 SCA10 patients (15%) ( p < 0.001). In SCA3, abnormalities predominantly involved central generators. In contrast, most SCA10 patients exhibited normal SSEPs, with only a few isolated cortical responses and interval abnormalities. No significant associations were found between SSEP abnormalities and demographic, clinical, imaging, or genetic variables in either group. SCA3 shows widespread somatosensory dysfunction, whereas SCA10 patients, particularly in Southern Brazil, show preserved SSEPs consistent with pure cerebellar ataxia. These findings highlight distinct neurophysiological signatures in SCAs, reinforcing their heterogeneity and supporting SSEPs as candidate markers for differential characterization, requiring validation.
- Open Access
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-008
Prevalence and predictors of low bone mineral density in Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease affecting the postsynaptic neuromuscular junction. Treatment often includes corticosteroids, which may reduce bone mass. To evaluate the prevalence and predictors of low bone mineral density (BMD) in MG patients. A cross-sectional study included patients over 18 years with MG followed at the Neuromuscular Diseases Service, Hospital de Clínicas, Universidade Federal do Paraná (2018–2022). Data were obtained through clinical evaluation, medical records, MG Composite Scale, and Quantitative MG Test. Lumbar spine and proximal femur BMD were assessed using a GE Lunar densitometer, with T or Z-scores according to age/menopausal status. Logistic regression identified factors independently associated with BMD alterations. In total, 92 patients (64.1% female, mean age: 51.3 years) were included, of whom 79.3% had early-onset MG. Past or present corticosteroid use were reported in 94.5 and 45.6%, respectively. Only 27.6% practiced regular physical activity, though most had adequate calcium intake. There were six (7.8%) patients with fragility fractures, and ⅕ were at high fracture risk according to the FRAX results. We found that BMD alterations occurred in 43.5% of patients. No significant association was found with corticosteroid use or MG severity. Age was independently associated with BMD (OR = 1.06, 95% CI: 1.03–1.09, p = 0.0005). A cutoff age ≥ 49 years yielded 82.5% sensitivity, 63.5% specificity, and an area under the ROC curve of 0.72 (95% CI: 0.61–0.83). Reduced BMD is frequent in MG, highlighting the importance of screening and prevention of low bone mass, osteoporosis, and fragility fractures, particularly in patients over 49 years, regardless of corticosteroid use or MG severity.
- 11 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (05) , 001-008
Open AccessPrevalence and predictors of low bone mineral density in Myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease affecting the postsynaptic neuromuscular junction. Treatment often includes corticosteroids, which may reduce bone mass. To evaluate the prevalence and predictors of low bone mineral density (BMD) in MG patients. A cross-sectional study included patients over 18 years with MG followed at the Neuromuscular Diseases Service, Hospital de Clínicas, Universidade Federal do Paraná (2018–2022). Data were obtained through clinical evaluation, medical records, MG Composite Scale, and Quantitative MG Test. Lumbar spine and proximal femur BMD were assessed using a GE Lunar densitometer, with T or Z-scores according to age/menopausal status. Logistic regression identified factors independently associated with BMD alterations. In total, 92 patients (64.1% female, mean age: 51.3 years) were included, of whom 79.3% had early-onset MG. Past or present corticosteroid use were reported in 94.5 and 45.6%, respectively. Only 27.6% practiced regular physical activity, though most had adequate calcium intake. There were six (7.8%) patients with fragility fractures, and ⅕ were at high fracture risk according to the FRAX results. We found that BMD alterations occurred in 43.5% of patients. No significant association was found with corticosteroid use or MG severity. Age was independently associated with BMD (OR = 1.06, 95% CI: 1.03–1.09, p = 0.0005). A cutoff age ≥ 49 years yielded 82.5% sensitivity, 63.5% specificity, and an area under the ROC curve of 0.72 (95% CI: 0.61–0.83). Reduced BMD is frequent in MG, highlighting the importance of screening and prevention of low bone mass, osteoporosis, and fragility fractures, particularly in patients over 49 years, regardless of corticosteroid use or MG severity.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-6
Somatosensory evoked potentials in neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are rare antibody-mediated disorders of the central nervous system with a predilection for the spinal cord and optic nerves. Our objective is to evaluate the dorsolemniscal system using the somatosensory evoked potential, specifically the registration of the N20 and P40 waves. The Somatosensory evoked potentials (SSEP) were prospectively performed in 13 patients with NMOSD. All the patients were recruited from the outpatient clinic of a demyelinating diseases center from Southern Brazil. We evaluated 12 female with mean age of 42 years-old and one man of 25 years-old. When categorized in relation to the variable SSEP (Normal vs. Abnormal), there was a statistical difference in relation to N20, N21 and P40 latencies. SSEP showed a significant increase in N20 and P40 latencies. SSEP is a non-invasive, painless, fast and low-cost exam which provides neurophysiological data for diagnosis of NMOSD.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-6
Somatosensory evoked potentials in neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are rare antibody-mediated disorders of the central nervous system with a predilection for the spinal cord and optic nerves. Our objective is to evaluate the dorsolemniscal system using the somatosensory evoked potential, specifically the registration of the N20 and P40 waves. The Somatosensory evoked potentials (SSEP) were prospectively performed in 13 patients with NMOSD. All the patients were recruited from the outpatient clinic of a demyelinating diseases center from Southern Brazil. We evaluated 12 female with mean age of 42 years-old and one man of 25 years-old. When categorized in relation to the variable SSEP (Normal vs. Abnormal), there was a statistical difference in relation to N20, N21 and P40 latencies. SSEP showed a significant increase in N20 and P40 latencies. SSEP is a non-invasive, painless, fast and low-cost exam which provides neurophysiological data for diagnosis of NMOSD.
- Open Access
- 9 May 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (05) , 001-003
Paul Hoffmann and the cutaneous silent period test
We herein present aspects of the biography of Professor Paul Hoffmann, covering his main works, mainly the article describing the cutaneous silent period, a new technique when it was published in 1922, with a review of its importance, its role in clinical neurophysiology, and its clinical application.
- 9 May 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (05) , 001-003
Open AccessPaul Hoffmann and the cutaneous silent period test
We herein present aspects of the biography of Professor Paul Hoffmann, covering his main works, mainly the article describing the cutaneous silent period, a new technique when it was published in 1922, with a review of its importance, its role in clinical neurophysiology, and its clinical application.
- 31 October 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 1019-1022
A TPM2 mutation causes congenital myopathy with fibre-type disproportion
We report a 9-year-old girl with delayed motor milestones and respiratory difficulty since birth. She presented as a floppy infant, with generalised muscle wasting, dysphagia and facial weakness. The muscle biopsy of the biceps brachii revealed congenital fibre-type disproportion (CFTD) and Sanger sequencing detected a pathogenic variant in the beta-tropomyosin (TPM2) gene (c.415_417delGAG; p.Glu139del). There has been only one previous report of CFTD associated with p.Glu139del in the TPM2 gene.
- 31 October 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 1019-1022
A TPM2 mutation causes congenital myopathy with fibre-type disproportion
We report a 9-year-old girl with delayed motor milestones and respiratory difficulty since birth. She presented as a floppy infant, with generalised muscle wasting, dysphagia and facial weakness. The muscle biopsy of the biceps brachii revealed congenital fibre-type disproportion (CFTD) and Sanger sequencing detected a pathogenic variant in the beta-tropomyosin (TPM2) gene (c.415_417delGAG; p.Glu139del). There has been only one previous report of CFTD associated with p.Glu139del in the TPM2 gene.
- Open Access
- 7 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (02) , 001-004
Myopathy due to carnitine palmitoyltransferase II deficiency: updating genetic aspects of the first publication in Brazil
Carnitine palmitoyltransferase II (CPT II) deficiency is an autosomal recessive inherited disorder related to lipid metabolism affecting skeletal muscle. The first cases of CPT II deficiency causing myopathy were reported in 1973. In 1983, Werneck et al published the first two Brazilian patients with myopathy due to CPT II deficiency, where the biochemical analysis confirmed deficient CPT activity in the muscle of both cases. Over the past 40 years since the pioneering publication, clinical phenotypes and genetic loci in the CPT2 gene have been described, and pathogenic mechanisms have been better elucidated. Genetic analysis of one of the original cases disclosed compound heterozygous pathogenic variants (p.Ser113Leu/p.Pro50His) in the CPT2 gene. Our report highlights the historical aspects of the first Brazilian publication of the myopathic form of CPT II deficiency and updates the genetic background of this pioneering publication.
- 7 February 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (02) , 001-004
Open AccessMyopathy due to carnitine palmitoyltransferase II deficiency: updating genetic aspects of the first publication in Brazil
Carnitine palmitoyltransferase II (CPT II) deficiency is an autosomal recessive inherited disorder related to lipid metabolism affecting skeletal muscle. The first cases of CPT II deficiency causing myopathy were reported in 1973. In 1983, Werneck et al published the first two Brazilian patients with myopathy due to CPT II deficiency, where the biochemical analysis confirmed deficient CPT activity in the muscle of both cases. Over the past 40 years since the pioneering publication, clinical phenotypes and genetic loci in the CPT2 gene have been described, and pathogenic mechanisms have been better elucidated. Genetic analysis of one of the original cases disclosed compound heterozygous pathogenic variants (p.Ser113Leu/p.Pro50His) in the CPT2 gene. Our report highlights the historical aspects of the first Brazilian publication of the myopathic form of CPT II deficiency and updates the genetic background of this pioneering publication.
- Open Access
- 25 January 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (01) , 001-007
Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics
Background Myasthenia gravis (MG) is an autoimmune disease usually caused by antibodies against the acetylcholine receptor (AChR-Abs), muscle-specific tyrosine kinase (MuSK-Abs), or low-density lipoprotein receptor-related protein 4 (LRP4-Abs). However, there are MG patients who do not have these antibodies and are thus said to have triple-seronegative (triple-SN) MG. Objective This study aims to describe the frequency and clinical and epidemiological characteristics of patients with triple-SN MG. Methods This was a retrospective cross-sectional study carried out through the analysis of medical records. Descriptive and analytical statistical analysis was performed comparing subgroups of myasthenic patients, classified according to serological profile. Results The sample population consisted of 93 MG patients: 85 were positive for antibodies, 80 (86%) with AChR-Abs, 5 (5.4%) with MuSK-Abs, and no MG patients with LRP4-Abs. Eight patients (8.6%) had triple-SN MG; they had a median age at disease onset of 30 years (21-45). Their most common initial symptoms were ptosis, diplopia, and generalized weakness. Most patients presented with mild symptoms at their last visit, reflecting a median MG composite scale score of 4 (0-6), and 75% of patients had an adequate response to treatment. Conclusion Our study showed a low frequency of triple-SN MG in Brazilian MG patients. Triple-SN MG was predominant in females, who presented with ptosis, diplopia, and generalized weakness, and most patients had an adequate response to immunosuppressive treatment. There was no significant difference between triple-SN MG and the other subgroups.
- 25 January 2024
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 82 (01) , 001-007
Open AccessTriple-seronegative myasthenia gravis: clinical and epidemiological characteristics
Background Myasthenia gravis (MG) is an autoimmune disease usually caused by antibodies against the acetylcholine receptor (AChR-Abs), muscle-specific tyrosine kinase (MuSK-Abs), or low-density lipoprotein receptor-related protein 4 (LRP4-Abs). However, there are MG patients who do not have these antibodies and are thus said to have triple-seronegative (triple-SN) MG. Objective This study aims to describe the frequency and clinical and epidemiological characteristics of patients with triple-SN MG. Methods This was a retrospective cross-sectional study carried out through the analysis of medical records. Descriptive and analytical statistical analysis was performed comparing subgroups of myasthenic patients, classified according to serological profile. Results The sample population consisted of 93 MG patients: 85 were positive for antibodies, 80 (86%) with AChR-Abs, 5 (5.4%) with MuSK-Abs, and no MG patients with LRP4-Abs. Eight patients (8.6%) had triple-SN MG; they had a median age at disease onset of 30 years (21-45). Their most common initial symptoms were ptosis, diplopia, and generalized weakness. Most patients presented with mild symptoms at their last visit, reflecting a median MG composite scale score of 4 (0-6), and 75% of patients had an adequate response to treatment. Conclusion Our study showed a low frequency of triple-SN MG in Brazilian MG patients. Triple-SN MG was predominant in females, who presented with ptosis, diplopia, and generalized weakness, and most patients had an adequate response to immunosuppressive treatment. There was no significant difference between triple-SN MG and the other subgroups.